Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 14/20 | 0.52 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | CDK2 | P24941 | 1/20 | 0.42 |
| ▸ | CTSL | P07711 | 1/20 | 0.41 |
| ▸ | ELANE | P08246 | 1/20 | 0.41 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20028767 | 1.00 | CAPN1 (0.52) | CAPN1KDRCDK2CTSLELANE | |
| SCHEMBL30133673 | 0.94 | CAPN1 (0.59) | CAPN1CTSL | |
| SCHEMBL20028395 | 0.94 | CAPN1 (0.59) | CAPN1CTSL | |
| SCHEMBL20027659 | 0.91 | CAPN1 (0.52) | CAPN1C3AR1 | |
| SCHEMBL21854173 | 0.91 | CAPN1 (0.52) | CAPN1C3AR1 | |
| SCHEMBL22897192 | 0.90 | CAPN1 (0.42) | CAPN1C3AR1 | |
| SCHEMBL21854239 | 0.89 | CAPN1 (0.50) | CAPN1 | |
| SCHEMBL20027481 | 0.89 | CAPN1 (0.50) | CAPN1 | |
| SCHEMBL22897064 | 0.89 | CAPN1 (0.54) | CAPN1 | |
| SCHEMBL21854107 | 0.88 | CAPN1 (0.53) | CAPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11339130-B1 | Calpain modulators and therapeutic uses thereof | BLADE THERAPEUTICS, INC. (US) | 2022-05-24 | — | — | US | disclosed |
| US-10934261-B2 | Calpain modulators and therapeutic uses thereof | BLADE THERAPEUTICS, INC. (US) | 2021-03-02 | — | — | US | disclosed |
| US-10894776-B2 | — | — | 2021-01-19 | — | — | US | disclosed |
| WO-2018064119-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | BLADE THERAPEUTICS, INC. (US) | 2018-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10934261-B2 | Calpain modulators and therapeutic uses thereof | CAPNS1, CAPN9, CAPN1 | CAPN1 3/4885KDR 4332/4885CDK2 1516/4885 |
| US-10894776-B2 | — | CAPNS1, CAPN9, CAPN2 | CAPN1 4/4885KDR 4651/4885CDK2 980/4885 |
| US-11339130-B1 | Calpain modulators and therapeutic uses thereof | CAPNS1, CAPN9, CAPN1 | CAPN1 3/4885KDR 4332/4885CDK2 1516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.